{
    "root": "316e6fee-f10a-35f9-e063-6394a90a77ac",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cyclobenzaprine Hydrochloride",
    "value": "20250328",
    "ingredients": [
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICIFIED MICROCRYSTALLINE CELLULOSE (50 .MICRO.M)",
            "code": "DVB3KG8URF"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
            "code": "0VE05JYS2P"
        }
    ],
    "indications": "cyclobenzaprine hydrochloride tablets , usp indicated adjunct rest physical therapy relief muscle spasm associated acute , painful musculoskeletal conditions . improvement manifested relief muscle spasm associated signs symptoms , namely , pain , tenderness , limitation motion , restriction activities daily living . cyclobenzaprine hydrochloride tablets used short periods ( 2 3 weeks ) adequate evidence effectiveness prolonged available muscle spasm associated acute , painful musculoskeletal conditions generally short duration therapy longer periods seldom warranted . cyclobenzaprine hydrochloride tablets found effective treatment spasticity associated cerebral spinal cord disease , children cerebral palsy .",
    "contraindications": "patients , recommended dose cyclobenzaprine hydrochloride tablets 5 mg three times day . based individual patient response , dose may increased 10 mg three times day . cyclobenzaprine hydrochloride tablets periods longer 2 3 weeks recommended ( usage ) . less frequent dosing considered hepatically impaired elderly patients ( : impaired hepatic function , elderly ) .",
    "warningsAndPrecautions": "cyclobenzaprine hydrochloride tablets , usp available containing 7.5 mg cyclobenzaprine hydrochloride , usp . 7.5 mg tablets white off-white film-coated , round tablets debossed 021 one side plain side . available follows : ndc 68071-3805-7 bottles 21 tablets ndc 68071-3805-1 bottles 15 tablets store 20°c 25°c ( 68°f 77°f ) . [ usp controlled room temperature . ] dispense tight , light-resistant container defined usp using child-resistant closure . manufactured : northstaetsr rx llc memphis , tn 38141. toll-free : 1-800-206-7821 manufactured : rubicon research ltd. , thane 421506 , india . iss . 07/2024",
    "adverseReactions": "hypersensitivity component product concomitant monoamine oxidase ( mao ) inhibitors within 14 days discontinuation . hyperpyretic crisis seizures deaths occurred patients receiving cyclobenzaprine ( structurally similar tricyclic antidepressants ) concomitantly mao inhibitor drugs . acute recovery phase myocardial infarction , patients arrhythmias , heart block conduction disturbances , congestive heart failure . hyperthyroidism .",
    "indications_original": "Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.\n                  Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.\n                  \n                     Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.\n                  \n                  Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.",
    "contraindications_original": "For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Use of cyclobenzaprine hydrochloride tablets for periods longer than 2 or 3 weeks is not recommended (see\n \n  INDICATIONS AND USAGE).\n\n \n                  Less frequent dosing should be considered for hepatically impaired or elderly patients (see\n \n  PRECAUTIONS: Impaired Hepatic Function, and\n \n  Use in the Elderly).",
    "warningsAndPrecautions_original": "Cyclobenzaprine Hydrochloride Tablets, USP are available containing 7.5 mg of cyclobenzaprine hydrochloride, USP.\n                  \n                  The 7.5 mg tablets are white to off-white film-coated, round tablets debossed with 021 on one side and plain on other side. They are available as follows:\n                  NDC 68071-3805-7 bottles of 21 tablets\n                  NDC 68071-3805-1 bottles of 15 tablets\n                  \n                  \n                  \n                     Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.]\n                  \n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  Manufactured for:\n                  Northstaetsr Rx LLC\n                  Memphis, TN 38141.\n                  Toll-Free: 1-800-206-7821\n                  \n                  Manufactured by:\n                  \n                  Rubicon Research Ltd.,\n                  Thane 421506, India.\n                  \n                  Iss. 07/2024",
    "adverseReactions_original": "Hypersensitivity to any component of this product\n                  Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.\n                  Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.\n                  Hyperthyroidism."
}